142 related articles for article (PubMed ID: 15696244)
1. Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure.
Conte MS; Lorenz TJ; Bandyk DF; Clowes AW; Moneta GL; Seely BL
Vasc Endovascular Surg; 2005; 39(1):15-23. PubMed ID: 15696244
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.
Alexander JH; Hafley G; Harrington RA; Peterson ED; Ferguson TB; Lorenz TJ; Goyal A; Gibson M; Mack MJ; Gennevois D; Califf RM; Kouchoukos NT;
JAMA; 2005 Nov; 294(19):2446-54. PubMed ID: 16287955
[TBL] [Abstract][Full Text] [Related]
3. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery.
Conte MS; Bandyk DF; Clowes AW; Moneta GL; Seely L; Lorenz TJ; Namini H; Hamdan AD; Roddy SP; Belkin M; Berceli SA; DeMasi RJ; Samson RH; Berman SS;
J Vasc Surg; 2006 Apr; 43(4):742-751; discussion 751. PubMed ID: 16616230
[TBL] [Abstract][Full Text] [Related]
4. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.
Mann MJ; Whittemore AD; Donaldson MC; Belkin M; Conte MS; Polak JF; Orav EJ; Ehsan A; Dell'Acqua G; Dzau VJ
Lancet; 1999 Oct; 354(9189):1493-8. PubMed ID: 10551494
[TBL] [Abstract][Full Text] [Related]
5. Edifoligide: a transcription factor decoy to modulate smooth muscle cell proliferation in vein bypass.
Hoel AW; Conte MS
Cardiovasc Drug Rev; 2007; 25(3):221-34. PubMed ID: 17919257
[TBL] [Abstract][Full Text] [Related]
6. Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial.
Conte MS; Bandyk DF; Clowes AW; Moneta GL; Namini H; Seely L
J Vasc Surg; 2005 Sep; 42(3):456-64; discussion 464-5. PubMed ID: 16171587
[TBL] [Abstract][Full Text] [Related]
7. The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics.
Alexander JH; Ferguson TB; Joseph DM; Mack MJ; Wolf RK; Gibson CM; Gennevois D; Lorenz TJ; Harrington RA; Peterson ED; Lee KL; Califf RM; Kouchoukos NT;
Am Heart J; 2005 Oct; 150(4):643-9. PubMed ID: 16209958
[TBL] [Abstract][Full Text] [Related]
8. Technical factors affecting autogenous vein graft failure: observations from a large multicenter trial.
Schanzer A; Hevelone N; Owens CD; Belkin M; Bandyk DF; Clowes AW; Moneta GL; Conte MS
J Vasc Surg; 2007 Dec; 46(6):1180-90; discussion 1190. PubMed ID: 18154993
[TBL] [Abstract][Full Text] [Related]
9. Molecular engineering of vein bypass grafts.
Conte MS
J Vasc Surg; 2007 Jun; 45 Suppl A():A74-81. PubMed ID: 17544027
[TBL] [Abstract][Full Text] [Related]
10. Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease.
Ehsan A; Mann MJ; Dell'Acqua G; Tamura K; Braun-Dullaeus R; Dzau VJ
Circulation; 2002 Apr; 105(14):1686-92. PubMed ID: 11940548
[TBL] [Abstract][Full Text] [Related]
11. Transcription factor decoys for the prevention of vein bypass graft failure.
Mann MJ; Conte MS
Am J Cardiovasc Drugs; 2003; 3(2):79-85. PubMed ID: 14727934
[TBL] [Abstract][Full Text] [Related]
12. New therapeutic possibilities for vein graft disease in the post-edifoligide era.
Cai X; Freedman NJ
Future Cardiol; 2006 Jul; 2(4):493-501. PubMed ID: 19804184
[TBL] [Abstract][Full Text] [Related]
13. Disparity in outcomes of surgical revascularization for limb salvage. Race and gender are synergistic determinants of vein graft failure and limb loss. Nguyen LL, Hevelone N, Rogers SO, Bandyk DF, Clowes AW, Moneta GL, Lipsitz S, Conte MS. Circulation. 2009; 119: 123-130.
Kreatsoulas C; Anand SS
Vasc Med; 2009 Nov; 14(4):397-9. PubMed ID: 19808727
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy for the extension of vein graft patency: a review.
Chandiwal A; Balasubramanian V; Baldwin ZK; Conte MS; Schwartz LB
Vasc Endovascular Surg; 2005; 39(1):1-14. PubMed ID: 15696243
[TBL] [Abstract][Full Text] [Related]
15. Single-center experience in endovascular treatment for infrainguinal bypass obstructions.
Baumann F; Engelberger RP; Makaloski V; Do DD; Baumgartner I; Diehm N
J Vasc Interv Radiol; 2012 Aug; 23(8):1055-62. PubMed ID: 22840804
[TBL] [Abstract][Full Text] [Related]
16. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy.
Ehsan A; Mann MJ; Dell'Acqua G; Dzau VJ
J Thorac Cardiovasc Surg; 2001 Apr; 121(4):714-22. PubMed ID: 11279413
[TBL] [Abstract][Full Text] [Related]
17. E2F decoy oligonucleotide for genetic engineering of vascular bypass grafts.
Mann MJ
Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):171-6. PubMed ID: 9593059
[No Abstract] [Full Text] [Related]
18. Biological treatment of vein grafts and stents in lower-extremity arterial reconstruction.
Morrissey NJ
Perspect Vasc Surg Endovasc Ther; 2007 Sep; 19(3):293-7. PubMed ID: 17911559
[TBL] [Abstract][Full Text] [Related]
19. Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia.
Schanzer A; Hevelone N; Owens CD; Beckman JA; Belkin M; Conte MS
J Vasc Surg; 2008 Apr; 47(4):774-781. PubMed ID: 18381138
[TBL] [Abstract][Full Text] [Related]
20. Midterm results of autologous saphenous vein and ePTFE pre-cuffed bypass surgery in peripheral arterial occlusive disease.
Donker JM; Ho GH; Te Slaa A; de Groot HG; van der Waal JC; Veen EJ; van der Laan L
Vasc Endovascular Surg; 2011 Oct; 45(7):598-603. PubMed ID: 21757494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
